Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Zoetis logoZoetis ZTS

The company said revenue for Q3 2025 rose 1% year over year to $2.4 billion, and net income rose 6% to $721 million, or $1.63 per diluted share, up 9%. On an organic operational basis, which excludes the effects of foreign exchange and certain acquisitions and divestitures, revenue grew 4%.

8-KResults of Operations and Financial ConditionFiled Period of report Summary published (UTC)

Key points

AI summary

  1. The company said revenue for Q3 2025 rose 1% year over year to $2.4 billion, and net income rose 6% to $721 million, or $1.63 per diluted share, up 9%. On an organic operational basis, which excludes the effects of foreign exchange and certain acquisitions and divestitures, revenue grew 4%.

  2. Zoetis said adjusted net income for Q3 2025 was $754 million, or $1.70 per adjusted diluted share. It said this excludes the net impact of $33 million for purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. On an organic operational basis, adjusted net income grew 9% and adjusted diluted EPS grew 12%.

  3. The company said revenue in its U.S. segment for Q3 was $1.3 billion, down 2% on a reported basis and up 3% on an organic operational basis. International segment revenue was $1.1 billion, up 3% on a reported basis and up 6% on an organic operational basis. It said U.S. livestock sales declined 9% on a reported basis, citing the divestiture of its medicated feed additive business as a factor.

  4. The company set its full-year 2025 revenue outlook at $9,400 million to $9,475 million, with organic operational growth of 5.5% to 6.5%. Its prior outlook, as of August 5, 2025, was $9,450 million to $9,600 million, or 6.5% to 8%. Its adjusted diluted EPS outlook of $6.30 to $6.40 is unchanged from the prior outlook.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

Zoetis reports Q3 2025 revenue of $2.4 billion, net income of $721 million

The company said revenue for Q3 2025 rose 1% year over year to $2.4 billion, and net income rose 6% to $721 million, or $1.63 per diluted share, up 9%. On an organic operational basis, which excludes the effects of foreign exchange and certain acquisitions and divestitures, revenue grew 4%.

Source · Based on the filing body and exhibits

Adjusted Net Income $754 million, Excluding Net $33 million in Significant Items

Zoetis said adjusted net income for Q3 2025 was $754 million, or $1.70 per adjusted diluted share. It said this excludes the net impact of $33 million for purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. On an organic operational basis, adjusted net income grew 9% and adjusted diluted EPS grew 12%.

Source · Based on the filing body and exhibits

Q3 Segment Revenue: U.S. $1.3 billion, International $1.1 billion

The company said revenue in its U.S. segment for Q3 was $1.3 billion, down 2% on a reported basis and up 3% on an organic operational basis. International segment revenue was $1.1 billion, up 3% on a reported basis and up 6% on an organic operational basis. It said U.S. livestock sales declined 9% on a reported basis, citing the divestiture of its medicated feed additive business as a factor.

Source · Based on the filing body and exhibits

Zoetis revises 2025 full-year revenue outlook to $9,400 to $9,475 million

The company set its full-year 2025 revenue outlook at $9,400 million to $9,475 million, with organic operational growth of 5.5% to 6.5%. Its prior outlook, as of August 5, 2025, was $9,450 million to $9,600 million, or 6.5% to 8%. Its adjusted diluted EPS outlook of $6.30 to $6.40 is unchanged from the prior outlook.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗
Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.